
Augustine Therapeutics Secures EUR 17 Million in Series A Funding to Propel Lead Candidate into Clinical Development for Neurological Diseases
Augustine Therapeutics, a pioneering biotech firm dedicated to advancing treatments for neurodegenerative and cardiometabolic diseases, has successfully closed its Series A funding round with EUR 17 million (USD 18.5 million). Asabys Partners led the financing, joined by Eli Lilly and…












